stock

Abbvie Inc (ABBV)

Share

Stay up to date

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Financial Statements

Key Info

  • Industry: Research and Development in Biotechnology (except Nanobiotechnology)
  • Sector: Professional, Scientific, and Technical Services
  • CEO Name: Richard Gonzalez

Key Statistics

  • Stock Price: $161.24
  • Dividend Yield: 3.8%
  • Market Capitalization: $276,022,792,848
  • Shares Outstanding: 1,765,867,781
  • Number of Employees: 50,000
  • Trailing 12-Month EPS: $3.36
  • Trailing 12-Month DPS: $5.98
  • Payout Ratio: 178.0%

Important Dates

  • Next Earnings Date: 2024-07-25
  • Next Ex-Dividend Date: 2024-04-12

Price Trends

  • Current Stock Price: $161.24
  • 52-week high: $181.2
  • 52-week low: $125.85
  • 200-day moving average: $162.14
  • 50-day moving average: $162.28

Performance

  • 1-Month Price Return: -3.2%
  • 3-Month Price Return: -11.4%
  • 6-Month Price Return: 15.0%
  • 1-Year Price Return: 19.2%
  • 2-Year Price Return: 12.6%
  • 5-Year Price Return: 152.7%

Visit the Passiv Stock Directory

Data provided by IEX Cloud

For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast